Biotech and Pharmaceutical Transactions
Catalyzing US‑China Biotech Partnerships & Licensing Deals
Biotech and Pharmaceutical Transactions
Catalyzing US‑China Biotech Partnerships & Licensing Deals
What We Do
- Out-licensing and in-licensing deals
Facilitating high-value transactions that enable biotech companies to expand pipelines and global reach.
- Cross-border collaboration
Bridging international markets, with a strong focus on partnerships between Chinese and global pharmaceutical companies.
- Capital acquisition
Assisting in securing funding to support business
- Talent acquisition
Supporting companies in attracting skilled professionals essential for scientific and commercial success
Our Strengths
- Extensive industry network
- Established relationships with thousands of biopharma professionals worldwide
- Direct access to key decision-makers for faster deal flow
- Established relationships with thousands of biopharma professionals worldwide
- Cross-border transaction guidance
- Proven track record navigating complex international deals, especially China-global collaborations
- Proven track record navigating complex international deals, especially China-global collaborations
- Strategic partnership development
- Identification and vetting of high-value opportunities across therapeutic areas
- End-to-end assistance from initial outreach to final agreement
- Identification and vetting of high-value opportunities across therapeutic areas
- Deep market intelligence
- Continuous monitoring of biotech and pharma trends to inform partnering strategy
- Data-driven recommendations to maximize asset value and minimize risk
- Continuous monitoring of biotech and pharma trends to inform partnering strategy
John Xu, MD, MBA, MS, President & Founder
John brings over two decades of expertise in biopharmaceutical research, business development, and cross-border licensing. A graduate of Shanghai Medical University, John began their career with 14 years of research experience in oncology at Bristol Myers Squibb and CNS at Wyeth.
Building on this scientific foundation, John transitioned into business development roles within China’s leading CROs, including WuXi AppTec and CrownBio, where they led strategic partnerships and client expansion.
For the past eight years, John has focused on both in-licensing and out-licensing deals across the U.S. and China, facilitating high-impact transactions and acting as a key connector in the global biotech ecosystem.
Highlights of Leadership & Impact
•Deep network of over 200 China-based biotech clients
•Business development advisor to 10+ U.S.-based venture capital firms, biotech hubs, and platform companies
• 10 term sheets in the past 15 months
•Built and maintained a powerful global network:
14,500+ LinkedIn connections
20+ WeChat groups, each with 500 biotech professionals